COMPOSITIONS PHARMACEUTIQUES ET RÉGIMES POSOLOGIQUES DESTINÉS À UNE UTILISATION CLINIQUE D'ANTICORPS ANTI-ANTIGÈNE 2 DE CELLULES DENDRITIQUES DU SANG

Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythemato...

Full description

Saved in:
Bibliographic Details
Main Authors KREBS, Mark, R., H, SULE, Shantanu, MARTIN, David, RABAH, Dania, DAI, David
Format Patent
LanguageFrench
Published 06.03.2019
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus eiythernatosus, and discoid lupus erythematosus, and cytokine release syndrome.
Bibliography:Application Number: MA20170044763